Clinical trials: Pioglitazone
Fatty Liver, Nonalcoholic Steatohepatitis
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00013598
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes, Secondary Drug Failure
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
- Trial name
- NCT00609856
- Testing
- pioglitazone, insulin glargine
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Skane University Hospital
Kidney Transplantation, Insulin Resistance
Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes
The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.
- Conditions
- Kidney Transplantation, Insulin Resistance, Atherosclerosis
- Trial name
- NCT00598013
- Testing
- Pioglitazone
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus, Insulin Resistance
Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin
The goal of the study is to demonstrate whether a switch from insulin therapy to an oral therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control (increase in HbA1c by more than 0.5 %) within a 6…
- Trial name
- PIOswitch (NCT00576784)
- Testing
- pioglitazone and glimepiride
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- IKFE Institute for Clinical Research and Development
Type 2 Diabetes
Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin
In type 2 diabetic patients with poor glycemic control despite maximum "classic" oral treatment, bed time insulin therapy may lead to a parallel increase in abdominal visceral and subcutaneous fat, whereas pioglitazone treatment…
- Trial name
- NCT00159211
- Testing
- UMULINE NPH, pioglitazone
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Type 2
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment
- Trial name
- NCT00290940
- Testing
- CS-917, metformin hydrochloride, pioglitazone
- Where
- 66 sites in United States
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Growth Hormone Deficiency
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growth hormone-replaced adults…
- Trial name
- NCT00459940
- Testing
- Pioglitazone
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Congenital Adrenal Hyperplasia
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia, an autosomal recessive condition, is mainly caused by mutations in the gene 21-hydroxylase and is treated with glucocorticoids in a slightly supraphysiological dose.
- Trial name
- NCT00151710
- Testing
- Pioglitazone
- Where
- Netherlands
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes, Hypertension
Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Hypertension, Dyslipidemia, Diabetic Nephropathy
- Trial name
- NCT00419484
- Testing
- pioglitazone
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Dokkyo Medical University
Healthy Subjects
Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.
The study is designed to test the hypothesis in healthy subjects that candesartan and pioglitazone provide additional vascular relaxing or modulating effects in addition to their blood-pressure and blood glucose level reducing…
- Trial name
- NCT00154037
- Testing
- Pioglitazone (drug) and/or candesartan (drug)
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
Type 2 Diabetes
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately…
- Trial name
- NCT00280865
- Testing
- Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling
- Where
- 110 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Obesity, Metabolic Syndrome
Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat.
- Conditions
- Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT00352287
- Testing
- Recombinant human growth hormone; pioglitazone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Stanford University
Coronary Atherosclerosis, Inflammation
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
In this study, we, the investigators at National Taiwan University Hospital, will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance (pioglitazone) on the progression and compositional change…
- Conditions
- Coronary Atherosclerosis, Inflammation, Coronary Heart Disease
- Trial name
- NCT00155350
- Testing
- pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
HIV-Associated Lipodystrophy Syndrome, HIV Infections
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
The aim of this randomized study is to compare the effect of pioglitazone versus placebo on change in limb fat in HIV 1-infected patients treated with antiretroviral therapy for at least 6 months and with clinical lipoatrophy.
- Trial name
- NCT00148850
- Testing
- Pioglitazone
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Insulin Resistance, Diabetes Mellitus
A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)
The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2…
- Trial name
- NCT00015626
- Testing
- Metformin, skin biopsy, diet and exercise
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Center for Research Resources (NCRR)